Zeria

Novo Nordisk announces positive phase 3 results for haemophilia treatment

However, Novo Nordisk plans to submit concizumab for regulatory approval for this indication in the second half of 2022 in the US and Japan, and then in 2023 in the EU

Cancer Research UK urges government to realise ‘science superpower’ ambitions as new report highlights ‘huge’ economic value

a ‘science superpower’ and commit more money towards UK R&D if we’re to continue to sit at the ‘top table’ with the likes of Germany and Japan.

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

Dr Ken Kato, chief of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, said: “This data, which shows tislelizumab plus chemotherapy extended patients’ lives by a median of ... Through a collaboration and licence

Novartis announces promising five-year data for leukaemia treatment Kymriah

The ELIANA trial was the first worldwide CAR T-cell therapy registration study, assessing patients in 25 centres in 11 countries including the EU, the US, Canada, Australia and Japan.

Eli Lilly and Incyte's Olumiant receives FDA approval for alopecia

Eli Lilly anticipates that regulatory decisions will be made for Olumiant in AA in the EU and Japan later this year. .

[ Previous 5 results ] 9 10 11 12 13 14 15 16 17 18 [ Next 5 results ]